Navigation Links
Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results

further clinical study results to potentially establish Inovio's DNA delivery technology as the delivery method of choice for localized administration of DNA treatments."

Enrollment of this study has been completed and further results are expected in the second half of 2007.

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly enhance the potency of such immunotherapies.

Inovio's DNA-based immunotherapy products consist of DNA plasmids and the Elgen and MedPulser DNA delivery systems. DNA plasmids are designed to express antigens that can induce an immune response specific to a cancer or infectious disease-causing organism. These plasmids are created synthetically and readily manufactured using well-established bacterial fermentation and purification technology. After a plasmid is delivered into muscle or tumor cells, production of the desired antigens may then induce a preventive or therapeutic immune response against the targeted disease. Inovio's advanced electroporation devices facilitate delivery and expression of such immunotherapies and have been shown in primate studies to boost antibody and T-cell immune response by orders of magnitude over DNA plasmid alone, suggesting the potential to provide better protection from complex infectious diseases such as HIV and hepatitis C as well as cancers such as prostate and breast cancers.

Inovio is poised to deliver advanced DNA-based immunotherapies, devices and know-how in this rapidly advancing field. The company is actively licensing its technology to pharmaceutical and biotechnology companies and supporting early stage clinical studies arising from
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
3. Inovio: DNA delivery technology shows positive human results
4. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
11. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
Post Your Comments:
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ... antibodies for the treatment of autoimmune diseases, asthma ... results for the second quarter ended June 30, 2014 ... "In the second quarter, we presented ... International Conference (ATS) demonstrating three novel mechanisms of ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, Inc. ... update on its pipeline and new product development ... to initiate a Phase 2a study of AZ-002 ... for the management of patients with acute repetitive ... Staccato -based product candidates for development - AZ-008 ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... Sept. 17 Pharmasset, Inc.,(Nasdaq: VRUS ) management ... held from September 22-25, 2008 at the Grand Hyatt ... Officer,will provide an overview of the company on Wednesday, ... To access a live webcast of Mr. Price,s ...
... CT Colonography Trial Raise Questions for,Patients, OAK ... CT Colonography Trial, published in the September 18 ... improvements in the technology,s,ability to diagnose intermediate- to ... testing is not as effective in diagnosing small ...
Cached Medicine Technology:Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 3ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 4ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 5
(Date:8/1/2014)... The Cardiovascular Research Foundation (CRF) has announced ... will be presented at next month,s Transcatheter Cardiovascular ... premier educational meeting specializing in interventional cardiovascular medicine, ... at the Walter E. Washington Convention Center in ... TCT often direct the course of patient therapies. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 ... Market Outlook to 2020", provides key market ... market. The report provides value, in millions ... average prices (in US dollars) within market ... Ultrasonic Generators and Argon Plasma Coagulation Generators. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 In today’s ... overall development of an individual. Hence, these methods need ... and employability skills can be inculcated. In this age ... boost to these conventional methods. Thus, learning management systems ... methodologies. , As of now, these are proving ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Women who serve ... alcohol than their civilian peers, a new study suggests. ... to consume alcohol. However, these researchers found that women ... men. This may be due to concerns about sexual ... use is tightly linked to sexual assault, both within ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Roaming the ... preserved mummy became famous as the "Ice Man" no doubt ... of that may still not have shielded the Ice Man, ... A human,s genetic risk for atherosclerosis, or "hardening of the ... thousands of years ago, a new study finds. ...
Breaking Medicine News(10 mins):Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 2Health News:United Kingdom Surgical Generators Market Size, Share, Analysis, Trends and Forecasts 2020 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Women in Military Drink Less Than Civilians, Report Shows 2Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2
... Structural biologists at Cold Spring Harbor Laboratory (CSHL) have ... for an allosteric inhibitor in a subtype of the ... cells. The newly discovered binding site -- ... because it is a potential target for drugs that ...
... , THURSDAY, June 16 (HealthDay News) -- ... else is making many people with middle and low ... grown a lot in the U.S., especially since the ... University of Virginia, said in news release from the ...
... By Denise Mann HealthDay Reporter , WEDNESDAY, June ... some people stopped flying out of fear of catching the virus ... new study shows that the "danger zone" for flu transmission is ... had been thought that this hot zone was much larger, according ...
... WEDNESDAY, June 15 (HealthDay News) -- Men who struggle with ... new study suggests. The study, by researchers from ... found that impotence, or erectile dysfunction, was more common among ... frequent the symptoms of the sleep disorder the higher the ...
... HealthDay Reporter , TUESDAY, June 14 (HealthDay News) -- For ... simple as sleeping on their left side, New Zealand researchers ... sleep on their left side had twice the risk of ... increase in risk [from right-sided sleeping] is small for the ...
... used cutting-edge stem cell technology to correct a genetic ... on a promising path that may one day lead ... diseases such as macular degeneration and retinitis pigmentosa which ... in an advance online publication of the journal ...
Cached Medicine News:Health News:CSHL structural biologists reveal novel drug binding site in NMDA receptor subunit 2Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 2Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 3Health News:Study Finds Two-Seat 'Hot Zone' for Flu Spread on Planes 4Health News:Impotence Linked to Restless Legs Syndrome 2Health News:Could Sleeping on Left Side Help Prevent Stillbirth? 2Health News:Could Sleeping on Left Side Help Prevent Stillbirth? 3Health News:Researchers report progress using iPS cells to reverse blindness 2